Most Read

ENHERTU is a particularly engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialised by the two firms. Around 136,000 cases of gastric cancer are diagnosed

Innovate UK awarded the grant as part of its Biomedical Catalyst 2022 research and development (R&D) competition. Alchemab is currently undertaking the preclinical studies to progress its antibodies

The company has also received additional funding from JLS Fund, Gron Ventures, Alumni Ventures, Palo Santo, Satori Capital, Negev Capital, and Route 66. It intends to use the

As per the strategic partnership and license agreement terms, Innovent will obtain an exclusive right for developing and commercialising the therapy in China. For the China rights, LG

Spesolimab has been developed to block the interleukin-36 receptor (IL-36R) activation. IL-36R is a signalling pathway in the immune system that is involved in the pathogenesis of many

The latest move follows a definitive agreement signed by the companies on 21 November this year. Merck stated that the tender offer will expire on 10 January next

Nitrase Therapeutics is deploying its NITROME platform for developing several therapies that target nitrases, a new enzymes class discovered by the company. The platform has created leads for

PreHevbrio has been approved for active immunisation against infection which is caused by all known subtypes of HBV in people aged 18 years and above. It is said

The designation will potentially facilitate the development and accelerate new therapies review for treating serious conditions which have unmet medical need. Moleculin noted that the company is now